IBTA e-News August 2019 now out

By 2nd September 2019 IBTA News
[31 August 2019] The IBTA's monthly e-News has been released and has emailed to all subscribers. To sign up to receive your copy, click here.

You can also read the IBTA e-News August 2019 edition in full online here.

Some of the highlights from this month's round-up:

  • This year's International Brain Tumour Awareness Week will be held from Saturday, 26th October to Saturday, 2nd November 2019, inclusive. We encourage you to organise an activity, such as a walk, a picnic, or an information seminar which will contribute to increased awareness about brain tumours.
  • There is limited information on the patterns of care and outcomes of high-grade gliomas in young adults, in particular, the impact it has on a person's employment. Before diagnosis, 71.6% were employed, but after diagnosis only 36 (32.0%) patients reported being employed. Most patients did not continue in employment after diagnosis.
  • The National Institute for Health and Care Excellence (NICE), in the UK, has published its draft recommendations on the use of cannabis-based medicinal products. NICE's public consultation, which is open until 5th September 2019, is asking for views on this draft guidance.
  • In a paper published in the Nature journal Communications Biology, scientists from the University of Sussex, UK, describe novel biomarkers within bodily fluids that are either exclusively found or over-expressed in cancer cells and, therefore, signal the presence of a tumour - in this case glioblastoma.
  • In a study published in the  journal, Science Translational Medicine, researchers showed that, in pre-clinical experiments, teriflunomide (a multiple sclerosis medicine) shrank glioblastomas and improved survival in mice. Because teriflunomide is already being used in people affected by multiple sclerosis, the safety profile of the drug is known.
  • Novocure and Zai Lab have received a "Chinese innovative medical device" designation for their cancer treatment, Optune, a Tumour Treating Fields delivery system that uses electric fields tuned to specific frequencies to disrupt cancer cell division, inhibiting tumour growth and causing affected cancer cells to die.
  • A Phase 2 trial, conducted at Sun Yat-Sen University Cancer Center (SYSUCC) in Guangzhou, China, and in collaboration with Guangxi Wuzhou Pharmaceutical Company, is investigating the first-line treatment of VAL-083 in combination with radiation therapy in newly-diagnosed, MGMT-unmethylated glioblastoma.

Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 6,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News every month by registering here.

To see an archive of existing e-News issues, click here.

let us know you agree to cookies

The IBTA website uses cookies to give you the best online experience in accordance with our cookies policy. If you are happy, please confirm by clicking the 'Accept' button below.